AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, covers production of five biopharmaceutical products with at least 35 batches annually, supporting global supply chain reliability. The agreement includes process transfer, scale-up, regulatory validation, and commercial production to meet approvals from EMA, FDA, MHRA, and PMDA. The Yokohama site, opening in 2027, will enhance AGC's global single-use bioproduction capacity and strengthen Japan's strategic role in resilient biopharma supply chains amid geopolitical risks.
On September 14, 2026, Bitcoin showed remarkable stability, slipping only 0.5% to about $76,800, while Asian tech stocks, including SoftBank, plunged due to renewed AI safety concerns. SoftBank shares dropped 13% after AI leaders called for a slowdow...
Hyperliquid has grown rapidly to become the third-largest crypto exchange by open interest, surpassing $11 billion. This marks it as a significant competitor to Binance in the perpetual futures market and a key player in the on-chain derivatives spac...
A small 2% investment in bitcoin made over a decade ago has grown to represent up to 85% of some Fundstrat clients' portfolios without additional purchases, illustrating bitcoin's extraordinary long-term growth. This shift highlights both the power o...
A survey by MSCI of 450 advisers in the US and Europe finds 71% plan to increase their use of active ETFs over the next two years, with 58% expecting new active ETF allocations to replace existing mutual funds. Advisers emphasize value, liquidity, an...
Oil prices have surged to nearly $108 following attacks on Saudi energy infrastructure and tensions near the Strait of Hormuz, raising inflation and interest rate worries globally. This rise in oil costs increases transportation and production expens...
